Theseus Pharmaceuticals Inc

NASDAQ THRX

Data sourced from

and

Daily

Download Data

Theseus Pharmaceuticals Inc Price to Earnings Ratio (P/E) on February 23, 2024

Theseus Pharmaceuticals Inc Price to Earnings Ratio (P/E) is NA on February 23, 2024, a NA change year over year. The price to earnings ratio (P/E ratio) compares the market price per share of a company's stock to its earnings per share (EPS). It is calculated by dividing the market capitalization by the net income, divided by the number of outstanding shares. This ratio provides insights into the market's valuation of a company's earnings. A higher P/E ratio indicates that investors are willing to pay a higher price for each unit of earnings, suggesting higher market expectations for future earnings growth.

Theseus Pharmaceuticals Inc 52-week high Price to Earnings Ratio (P/E) is -1.95 on July 14, 2023, which is NA below the current Price to Earnings Ratio (P/E).
Theseus Pharmaceuticals Inc 52-week low Price to Earnings Ratio (P/E) is -9.16 on May 04, 2023, which is NA below the current Price to Earnings Ratio (P/E).
Theseus Pharmaceuticals Inc average Price to Earnings Ratio (P/E) for the last 52 weeks is -4.74.

NASDAQ: THRX

Theseus Pharmaceuticals Inc

CEO	Dr. Iain D. Dukes D.Phil., DPHIL, M.A.
IPO Date	Oct. 7, 2021
Location	United States
Headquarters	245 Main Street, Cambridge, MA, United States, 02142
Employees	38
Sector	Healthcare
Industry	Biotechnology

Description

Theseus Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of targeted therapies for the treatment of cancer patients. Its lead product candidate is THE-630, a pan-KIT inhibitor for the treatment of gastrointestinal stromal tumors. The company also develops THE-349, a fourth-generation selective epidermal growth factor receptor inhibitor to address C797X-mediated resistance to first- or later-line osimertinib treatment in patients with non-small cell lung cancer. Its development programs address drug resistance mutations in key driver oncogenes, which are mutated genes that cause cancer. The company was incorporated in 2017 and is based in Cambridge, Massachusetts. As of February 14, 2024, Theseus Pharmaceuticals, Inc. operates as a subsidiary of Concentra Biosciences, LLC.

Key trends